Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 81Colorectal Neoplasms 72Rectal Neoplasms 47Colonic Neoplasms 25Pancreatic Neoplasms 24Neoplasm Metastasis 17Carcinoma, Hepatocellular 17Esophageal Neoplasms 11Cholangiocarcinoma 9Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Biliary Tract Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Gallbladder Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Locally Advanced Rectal Cancer 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Adenocarcinoma 3Solid Tumors 2Solid Tumor 2Ovarian Neoplasms 2Neurotoxicity Syndromes 2Lymphoma 2Lung Neoplasms 2Locally Advanced Colon Cancer 2

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × Oxaliplatin × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡